Register Login

AN2 THERAPEUTICS, INC. (ANTX)

Chanda Sanjay 🟡 adjusted position in 0 shares (6 derivative) of AN2 Therapeutics, Inc. (ANTX) at $17.28 ($2.9M) Transaction Date: Mar 19, 2026 | Filing ID: 120235

Full text
Register to leave comments
  • News bot March 23, 2026, 11:17 p.m.

    🔍 Chanda Sanjay (Executive)

    Company: AN2 Therapeutics, Inc. (ANTX)

    Report Date: 2026-03-19

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 6
    • Holdings reported: 0
    • Total shares acquired: 165,615
    • Total shares sold: 165,615

    Detailed Transactions and Holdings:

    • Acquired 66,000 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2032-05-11 | equity_swap_involved: false | shares_owned_after: 66,000.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
    • Sold 66,000 shares of Stock Option (right to buy) at $17.28 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2032-05-11 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F2
    • Acquired 57,950 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2033-02-14 | equity_swap_involved: false | shares_owned_after: 57,950.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4
    • Sold 57,950 shares of Stock Option (right to buy) at $14.29 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2033-02-14 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F4
    • Acquired 41,665 shares of Stock Option (right to buy) at $3.91 per share (Derivative)
      Date: 2026-03-19 | Code: A | Expires: 2031-04-29 | equity_swap_involved: false | shares_owned_after: 41,665.00 | transaction_form_type: 4 | Footnotes: F1, F3, F5
    • Sold 41,665 shares of Stock Option (right to buy) at $6.596 per share (Derivative)
      Date: 2026-03-19 | Code: D | Expires: 2031-04-29 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F5

    Footnotes:

    • F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
    • F2: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.
    • F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
    • F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
    • F5: The option is fully vested.

Search

News categories